WO1987007616A1 - Peptides involved in the pathogenesis of hiv infection - Google Patents
Peptides involved in the pathogenesis of hiv infection Download PDFInfo
- Publication number
- WO1987007616A1 WO1987007616A1 PCT/US1987/001294 US8701294W WO8707616A1 WO 1987007616 A1 WO1987007616 A1 WO 1987007616A1 US 8701294 W US8701294 W US 8701294W WO 8707616 A1 WO8707616 A1 WO 8707616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- peptides
- peptide
- amino acid
- virus
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 154
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 100
- 230000008506 pathogenesis Effects 0.000 title claims abstract description 11
- 208000031886 HIV Infections Diseases 0.000 title claims description 18
- 208000037357 HIV infectious disease Diseases 0.000 title claims description 16
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims description 16
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 108700004025 env Genes Proteins 0.000 claims description 18
- 101150030339 env gene Proteins 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 abstract description 19
- 208000015181 infectious disease Diseases 0.000 abstract description 9
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 235000001014 amino acid Nutrition 0.000 description 27
- 241000700605 Viruses Species 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 21
- 238000003556 assay Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 11
- 230000017960 syncytium formation Effects 0.000 description 10
- 241000283707 Capra Species 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100034353 Integrase Human genes 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108010078428 env Gene Products Proteins 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000007981 phosphate-citrate buffer Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108010012038 peptide 78 Proteins 0.000 description 2
- 229940125863 peptide 78 Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 241000714195 Aids-associated retrovirus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- VFBJEDFCUUCMBQ-UHFFFAOYSA-O azanium;sodium;antimony(3+);oxygen(2-);tungsten Chemical compound [NH4+].[O-2].[Na+].[Sb+3].[W] VFBJEDFCUUCMBQ-UHFFFAOYSA-O 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- WXKPPMQZRGORPB-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;acetate Chemical compound [Na+].CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O WXKPPMQZRGORPB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Peptides involved in the pathogenesis of human immunodeficiency virus (''HIV''). More particularly, this invention relates to peptides from the env region of the HIV genome and the use of such peptides in methods and compositions for preventing, treating, or detecting acquired immune deficiency syndrome (''AIDS'') infection.
Description
PEPTIDES INVOLVED IN THE PATHOGENESIS OF HIV INFECTION
TECHNICAL FIELD OF INVENTION
This invention relates to peptides involved in the pathogenesis of human immunodeficiency virus ("HIV"). More particularly, this invention relates to peptides from the env region of the HIV genome and the use of such peptides in methods and composi¬ tions for preventing, treating, or detecting acquired immune deficiency syndrome ("AIDS") infection.
BACKGROUND ART
Acquired immune deficiency syndrome ("AIDS"] is a disease characterized by severe or, typically, complete immunosuppression and attendant host sus- ceptibility to a wide range of opportunistic infec¬ tions and malignancies. AIDS' complete clinical manifestation is usually preceded by AIDS related complex ("ARCS"), a syndrome accompanied by symptoms such as lymphadenopathy, fever and weight loss. The human immunodeficiency virus ("HIV") retrovirus is thought to be the etiological agent
-2- responsible for AIDS infection and the ARCS syndrome [M. G. Sarngadharan et al., "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) From Patients With AIDS and Pre-AIDS", Science, 224, pp. 497-508 (1984)].* Between 85 and 100% of the AIDS/ARCS patient population test sero- positive for HIV [G. N. Shaw et al., "Molecular Char¬ acterization of Human T-Cell Leukemia (Lymphotropic) Virus Type III In The Acquired Immune Deficiency Syndrome", Science, 226, pp. 1165-70 (1984)].
Upon infection of a host, the primary tar¬ gets of the HIV virus are T-4 lymphocytes, also known as helper or inducer cells. T-4 lymphocytes interact with other specialized cell types of the immune system to confer immunity to or defense against infection. More specifically, T-4 lymphocytes stimu¬ late production of growth factors which are critical to the functioning of the immune system. For example, they act to stimulate B cells, the descendants of hemopoietic stem cells, which promote the production of defensive antibodies. They also activate macro- phages ("killer cells") to attack infected or other¬ wise abnormal host cells, and induce monocytes ("scavenger cells") to encompass and destroy invading microbes. Accordingly, when T-4 lymphocytes are rendered non-functional by HIV infection, this com¬ plex immune defense system is destroyed and the host becomes susceptible to a wide range of opportunistic infections. In addition to T-4 lymphocytes, the HIV virus has also been shown to infect central nervous
* In this application, human immunodeficiency virus ("HIV"), the generic term adopted by the human retrovirus subcommittee of the International Committee on Taxonomy of Viruses to refer to independent isolates from AIDS patients, including human T-cell lymphotropic virus type III ("HTLV-III"), lymphadenopathy-associated virus ("LAV") and AIDS-associated retrovirus ("ARV") will be used.
-3- system cells, macrophages and B lymphocytes [J. M. Ismach, "AIDS: Can The Nation Cope", Medical World News (August 25, 1985)].
The genome of retroviruses such as HIV contains three regions encoding structural proteins. The gag region encodes the core proteins of the virion. The pol region encodes the virion RNA-depen- dent DNA polymerase (reverse transcriptase). The env region encodes the major glycoprotein found in the membrane envelope of the virus and in the. cyto- plasmic membrane of infected cells. The capacity of the virus to attach to target cell receptors and to cause fusion of cell membranes are two HIV virus properties controlled by the env gene. These pro- perties are believed to play a fundamental role in the pathogenesis of the virus.
HIV env proteins arise from a precursor polypeptide that, in mature form, is cleaved into a large heavily glycosylated exterior membrane protein of about 481 amino acids — gpl20 — and a smaller transmembrane protein of about 345 amino acids which may be glycosylated — gp41 [L. Ratner et al., "Com¬ plete Nucleotide Sequence Of The Aids Virus, HTLV-III", Nature, 313, pp. 277-84 (1985)]. In the absence to date of effective treat¬ ments for AIDS, many efforts have centered on preven¬ tion of the disease. Such preventative measures include HIV antibody screening of all blood, organ and semen donors and education of AIDS high-risk groups regarding transmission of the disease.
Experimental or early-stage clinical treat¬ ment of AIDS and ARCS conditions have included the administration of antiviral drugs, such as HPA-23, phosphonoformate, suramin and ansamycin, which apparently interfere with replication of the virus by inhibiting its reverse transcriptase. Adminis¬ tration of some of these drugs in effective amounts
-4- has, however, been accompanied by undesirable and debilitating side effects. Other proposed methods for treating AIDS have focused the administration of alpha interferon or the application of hybridoma technology. Most of these treatment strategies are expected to require the co-administration of immuno- modulators, such as interleukin-2. However, while some of these treatments are promising, none has been shown to be truly effective. Recent studies have also demonstrated that
HIV is experiencing genetic drift in humans. At least two classes of the virus have now been identi¬ fied in AIDS patients in the United States. Further¬ more, patients having high levels of HIV neutralizing antibodies suffer more serious forms of the disease than those patients with poor neutralizing capabi¬ lities [Dr. William Haseltine, speech at Memorial Sloan-Kettering Cancer Center, October 9, 1985]. These recent observations suggest serious obstacles to the development of an effective vaccine or mono¬ clonal antibody-directed therapeutic method against HIV AIDS infections.
Accordingly, despite these developments to date, the need exists for the development of effective agents for the prevention, treatment and diagnosis of HIV and AIDS-related infections.
DISCLOSURE OF THE INVENTION
The present invention solves the problems referred to above by providing peptides involved in the pathogenesis of the HIV virus. According to one embodiment, the peptides of this invention are selected from the group consisting of peptides characterized by an amino acid sequence derived sub¬ stantially from the region between about amino acid 600 and amino acid 750 of the HIV env gene. This region is believed to have an important role in
-5- virus-mediated pathogenic events. More preferably, the peptides of this invention consist substantially of the following amino acid sequences of the HIV env gene — peptide 1: amino acids 616-632; peptide 2: amino acids 667-680; peptide 3: amino acids 627-639*; peptide 4: amino acids 728-751 and peptide 64: amino acids 627-639. This invention also includes the D-retro form of each of the above-identified pep¬ tides — those produced by synthesis with D amino acids in the opposite orientation, beginning with the carboxy terminal amino acid of the L form.
Other embodiments of this invention include peptide 5, which consists substantially of amino acids 426-450 of the HIV env gene, peptide 6, which consists substantially of amino acids 496-519 of the HIV env gene, peptide 31, which consists sub¬ stantially of amino acids 148-165 of the HIV env gene and peptide 78, which consists substantially of peptides 298-314 of the HIV env gene. This invention also includes the D-retro form of each the above-identified peptides. These peptides produce antisera which, in conventional assays, bind to the HIV virus, inhibit syncytium formation or neutralize the virus. In addition, the peptides themselves may be capable of inhibiting HIV-directed syncytium formation or neutralizing HIV in conventional assays. Such peptides, therefore, are useful in compositions
* Due to an inadvertent mislabelling of the peptide sample assayed, the 873,621 application referred to peptide 3 as amino acids 702-715 of the HIV env gene. Subsequent amino acid sequencing of the peptide sample demonstrated that the peptide labelled "peptide 3" in fact had the sequence: amino acids 627-639 of the HIV env gene. As employed in the present applica¬ tion, therefore, "peptide 3" refers to a peptide having the sequence of amino acids 627-639 of the HIV env gene. This is the same sequence as peptide 64. Thus, peptides 3 and 64 are identical. The two num- bers are used to distinguish the preparations of the two peptides.
and methods for preventing, treating and detecting AIDS infection.
The peptides of this invention comprise functional regions of the HIV env protein involved in virus-mediated events, such as adsorption to normal cells and syncytium formation, which con¬ tribute to the pathogenesis of the disease. The functional regions encompassed by these peptides also correspond to immunogenic determinants of the HIV env gene which are highly conserved. Accord¬ ingly, these peptides comprise segments of HIV env protein which are highly immunogenic and are in¬ volved in virus pathogenesis over the range of genetic variants of the HIV virus. The peptides of this invention may be advantageously used in vaccines or therapeutic com¬ positions which elicit antibodies reactive with the native env protein of the HIV virus or which inter¬ fere with the virus by neutralization or inhibition of syncytium formation. Furthermore, these peptides are easily modified in composition and conformation to improve the specific activity of those peptides against the HIV virus. In addition, these peptides may be used as diagnostic agents for detecting HIV infections.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts the amino acid sequences of each of peptides 1-6, 31, 64 and 78 of this inven¬ tion, as- well as that of the region between amino acid 600 and amino acid 750 of the HIV env gene. In this figure, the amino acids are represented by single letter codes as follows:
Phe: F Leu: L lie: I Met: M
Val : V Ser: S Pro : P Thr: T
Ala: A Tyr: Y His : H Gin: Q
Asn: N Lys : K Asp : D Glu: ε
Cys : C Trp : W Arg: R Gly: G
DETAILED DESCRIPTION OF THE INVENTION
Referring now to Figure 1, we prepared various peptides corresponding to segments of the env gene of the HIV genome and tested them in several conventional assays to demonstrate that they display activities reflecting their involvement in virus-mediated pathogenic events.
It should be understood that the present invention is not limited to the illustrative pep- tides depicted in Figure 1. Instead, a peptide falling within the scope of this invention may extend outside of or comprise less than the region between amino acid 600 and amino acid 750 of the HIV env gene, as long as a substantial part of that pep- tide is characterized by an amino acid sequence from that region, or segments or combinations thereof, and that peptide demonstrates the desired immuno- logical or biological activity against HIV. In addi¬ tion, peptides according to this invention include those having amino acid sequences which are longer or shorter in length than those of peptides 1-4 and 64 or which comprise segments or combinations thereof, as long as such peptides consist substan¬ tially of the region between amino acids 600-750 of the HIV env gene and demonstrate the desired immuno- logical or biological activity. Furthermore, pep¬ tides according to this invention include those characterized by a sequence of amino acids which is longer or shorter than that of any one of peptide 5, peptide 6, peptide 31 or peptide 78, or which comprise segments of each of those peptides and which display immunological or biological activity against HIV.
Accordingly, it should be understood that the specific selection of any one peptide within the peptides of this invention is not critical. Such a selection may be carried out by taking a number of peptides and testing them for their immunological
and biological activity against HIV as described herein.
The peptides according to this invention may be prepared by conventional synthesis using any of the known peptide synthesis methods, including synthesis on a solid support. The peptides of the invention may also be prepared in appropriate hosts transformed with DNA sequences that code for the desired peptide. For example, a peptide of this invention may be prepared by the fermentation of appropriate hosts that have been transformed with and which express a DNA sequence encoding that pep¬ tide. Alternatively, DNA sequences coding for several of the peptides of this invention may be linked together and those sequences may then be used to transform appropriate hosts to permit the expres¬ sion of peptides involved in the pathogenesis of HIV infection. A combination of such methods may also be employed. In a preferred embodiment of this invention, chemical synthesis alone is employed. By means of that method, the peptides of this invention are additionally advantaged because they are easily purified and are non-biological in origin.
The peptides of this invention are prefer- ably coupled to one or more carrier proteins, such as keyhole limpet hemocyanin ("KLH") before use in the compositions and methods described herein. The peptides are coupled to the carrier protein in various conventional ways, such as those described by M. Reichlin, "Use Of Glutaraldehyde As A Coupling
Agent For Proteins And Peptides", Methods In Enzvmoloqy, 70, pp. 159-65 (1980).
After preparing the peptide and coupling it to the carrier protein, if desired, the antigen is employed in the methods and compositions of this invention in a conventional manner. For example, the. peptide or coupled peptide, alone or in combi-
-9- nation with other peptides of this invention, is usually mixed with one or a combination of well- recognized adjuvants and additives, preferably by first dissolving the peptide, for example, in PBS with 0.1% SDS. In other embodiments of this inven¬ tion, the peptides may be linked to hydrophobic groups to build the adjuvant into the composition. Of course, it should be understood that other well- known methods of preparing therapeutic compositions may be employed using the peptides of this invention. The above-prepared compositions are then employed in a conventional manner for the treatment of HIV infections. Such methods of treatment and their dosage levels and requirements are well- recognized in the art and may be chosen by those of skill in the art from available methods and tech¬ niques. For example, the peptides of this invention may be combined with a pharmaceutically acceptable adjuvant for administration to an HIV-infected patient in a pharmaceutically acceptable manner and in an amount effective to lessen the severity of the HIV infection. The dosage and treatment regimens will depend upon factors such as the patient's health status, the severity and course of infection and the judgment of the treating physician.
Alternatively, the peptides of this inven¬ tion are useful in vaccines and methods for protec¬ ting humans against HIV infection for at least some period of time. The peptides may be employed in these vaccines and methods either alone or together with other peptides of this invention in a manner consistent with the conventional utilization of anti¬ gens in vaccines. For example, the peptides of this invention may be combined with pharmaceutically acceptable adjuvants conventionally employed in vaccines and administered in immunologically effec-
tive amounts to protect patients for some time against HIV infection.
Both the compositions and vaccines of this invention may be administered to patients via con- ventional modes of administration. The frequency of administration will depend upon factors such as the particular composition or vaccine employed and the condition of the patient. The need for subsequent treatments with these compositions or boosters of these vaccines will depend upon the results of the initial treatment or vaccination.
In addition, the peptides of this invention and the antibodies raised to them may be employed in presently available methods and kits designed to detect the presence of HIV and antibodies to HIV in blood, organ or semen samples.
In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
EXAMPLE I
A. Preparation Of Peptides Involved In The
Pathogenesis of HIV Infection
We synthesized peptides 1-6, 31, 64 and 78, corresponding to segments of the env gene of the HIV genome. These peptides are depicted in Figure 1, in which the amino acid numbering corresponds to that set forth for the env gene in L. Ratner et al., "Complete Nucleotide Sequence Of The AIDS Virus, HTLV-III", Nature, 313, pp. 277-84 (1985).
We synthesized the peptides using an im- proved version of the solid phase method described by R. B. Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis Of A Tetrapeptide", J. Am. Chem.
Soc. , 83, pp. 2149-54 (1963), using an Applied Bio- systems Model 430A peptide synthesizer and reagents and procedures as supplied by producer. In this improved method, we deblocked and cleaved the pro- tected peptides from the resin with liquid HF con¬ taining 10% anisole, in a variation of the method described by S. Sakakibara et al., "Use Of Anhydrous Hydrogen Fluoride In Peptide Synthesis. I. Behavior of Various Protective Groups In Anhydrous Hydrogen Fluoride", Bull. Chem. Soc. Jap., 40, pp. 2164-68 (1967).
We first purified the peptides cleaved from the resin by partition chromatography on a Sephadex LH20 column using n-Butanol/water (6/100) as eluent. The eluate was further pvirified by semi- preparative high pressure reversed phase chromatog¬ raphy on an Altex Ultrasphere-ODS column, by elution with a 0.1% TFA acetonitril gradient. After we hydrolyzed the eluate with 6N HC1 for 18 hours, we carried out amino acid analysis on a Beckman amino acid analyzer to confirm the amino acid sequences of the peptides produced.
B. Immunological Activity
Of The Peptides Of This Invention 1. Coupling Of Peptides To Carrier Proteins
In one embodiment of this invention, pep¬ tides 1-6,* 31, 64 and 78 were preferably coupled to one or more carrier proteins before use. Accordingly, we coupled each of those peptides prepared as described above to the carrier protein keyhole limpet haemo- cyanin (KLH, Sigma) by mixing 2 mg of peptide in
* Due to an inadvertent error, the 873,621 appli¬ cation stated that peptides 2 and 3 were used in non-coupled form. Peptides 2 and 3 as employed in the examples of both the '621 application and the present application were used in coupled form.
2 ml sodium phosphate buffer (O.IM, pH = 8) with 5 mg of KLH in 2 ml sodium phosphate buffer (O.IM, pH = 8). We then added 1 ml of a 0.25% glutaraldehyde solution to the mixture in several portions over a period of 1 hour. We stirred the resulting mixture for another 6 hours and then dialyzed it against PBS overnight.
For use in vaccine compositions, the pep¬ tides of this invention may be coupled with tetanus toxoid antigen, diphteria toxoid antigen or another natural or synthetic carrier suitable for use in humans using conventional techniques. Alternatively, the peptides may be coupled with a suitable adjuvant to enhance the immune response in the patient. The peptides may also be used in combination with any suitable synthetic low molecular weight carrier before use. Finally, an additional cysteine residue may be added to the C or N terminus of the peptide for coupl¬ ing to a suitable carrier by disulfide linkage.
2. Inoculation Of Test Animals
We emulsified each of the KLH-coupled pep¬ tides 1-6, 31, 64 and 78 with Freund's complete adjuvant in a 1:1 ratio. Subsequently, we inoculated groups of 3 BALB/CJ mice (Jackson Laboratory, Bar Harbor, Maine) by subcutaneous injection of
100 μg/250 μl of the emulsification into each mouse. On following days 14 and 35, each mouse received a booster injection of 100 μg/250 μl of the same coupled peptide emulsified 1:1 in Freund's incomplete adjuvant. Tail bleeds were taken on days 21 and 42,' with serum samples being stored at -20°C until the time of assay.
-13-
3. Immunological Assays i. ELISA With Antipeptide Sera Against env Peptide Coated Plates In this assay, we determined that antiserum raised in an animal by each of peptides 1-6, 31, 64 and 78 of this invention binds to that peptide. Accordingly, the peptides of this invention are immunogenic and elicit a response in test animals. To carry out the assay, we coated two of four 96-well microtiter plates (Nunc Imrauno I) with 50 μl of a mixture of 50 μg/ml uncoupled peptide in PBS (20mM phosphate, 150mM NaCl, pH = 7.2) and incubated the plates overnight at room temperature. The third and fourth plates, which served as controls for, respectively, the first and second plates, were treated identically to those plates but were not pre-coated with peptide. We then inverted the plates to empty all wells and washed the plates 3 times with PBS/0.05% Tween-20. The plates were blotted dry by gentle tapping over paper towels. After blotting the plates, we added 350 μl of a 5% fetal calf serum/PBS ("FCS/PBS") solution to each well and incubated the plates for 1 hour at room temperature. We then washed and blotted the plates as before.
We then assayed serum samples pooled from each group of 3 mice on the two pre-coated plates prepared as described above and on two control plates. In the first pre-coated plate, we assayed the antibody response to the immunogen peptide at an initial dilu¬ tion of 1:10, followed by serial 2-fold dilutions in 5% FCS/PBS. In the second plate, an initial serum dilution of 1:20 was followed by serial 3-fold dilu¬ tions in 5% FCS/PBS. After a 2 hour incubation period, we washed the plates and blotted them dry as described above. We then added 50 μl of 1:2000 dilution of goat anti-
mouse-IgG horseradish peroxidase ("HRP") (A.P., heavy and light chain specific, Cappel Laboratories) in 5% FCS/PBS to each well and incubated the plates at room temperature for 1 hour. We then washed the plates with PBS/0.05% Tween-20. We added 42 mM of 3, 3', 5, 5'-tetramethylbenzidine in dimethylsul- foxide ("TMB/DMSO"), 7.35 μl of 30% hydrogen peroxide ("H202") to 50 ml of O.IM sodium acetate-citric acid buffer (pH = 4.92). Subsequently, we added 50 μl of this solution to the wells using a 12 channel mul¬ tiple pipet. We stopped the enzyme reactions with 50 μl of 2M H2S04 when the less dilute samples reached an absorbance of 0.2 O.D. at 650 nm. We then analyzed the plates spectrophotometrically at 410 nm using a microplate reader (Dynatech MR600) and observed that antiserum against each of peptides 1-6, 31, 64 and 78 binds to that peptide.
ii. ELISA With Antipeptide
. Sera Against Virus-Coated Plates In this assay, we demonstrated that antisera raised against the peptides of this invention binds to HIV virus-coated plates.
We added 100 μl of carbonate buffer (pH = 9.6) containing 5% bovine serum albumin to each well of 96 well microtiter plates coated with authentic HIV virus (a gift of Dr. Robert Gallo) and incubated the plates at room temperature.* Virus-coated micro-
* Due to an inadvertent error, the 873,621 appli- cation referred to the preparation of HIV virus-coated plates. The virus-coated plates as employed in the examples of both the '621 application and the present application were a gift of Dr. Robert Gallo. It is our understanding that the plates used were in fact made, or at. least could have been made, by coating
96 well microtiter plates (Nunc Immuno I) with 100 μl of a mixture of 5 μg/ml authentic HIV virus in car¬ bonate buffer (pH = 9.6), incubating the plates overnight at 4°C, inverting the plates to empty all wells, washing the plates 3 times with deionized water and then blotting them.
titer plates are also available from Electronucleonics, Fairfield, New Jersey. Subsequently, we rinsed the plates 3 times with deionized water.
After blotting the plates, we added 100 μl of saline-P04(PBS) containing 20% normal goat serum to each well. We next added 5 μl of human test serum or control serum to each well and incubated the plates overnight at 4°C, or for 2 hours at room temperature. We then washed the plates 3 times with PBS containing 0.05% Tween-20 and blotted them.
We next added 100 μl of a 1:4000 dilution of 1% normal goat serum and goat anti-human-IgG HRP (heavy and light chain specific) in 0.05% PBS-Tween 20 to each.well and incubated the plates for 1 hour at room temperature. We had titrated the anti-human- IgG HRP before use to assure a proper final concentra¬ tion of indicator antibody. At the end of the hour incubation period, we rinsed the plates 2 times with 0.05% PBS-Tween-20 and once with plain PBS. We then added 100 μl of a solution of 0.005% H202 and 0.05% orthophenylene diamine ("OPD")* in Sorenson's phosphate citrate buffer (pH = 5) and allowed reaction for 20 minutes at room temperature in the dark.
We stopped the reaction by adding 50 μl of 4N H-SOA to each well. The plates were read by visual inspection or using a microplate reader at 490 nm.
Each plate had a series of "blank" control wells containing no human serum or anti-human IgG-HRF conjugate and to which one of the following had been added:
* This is a potential carcinogen which should be detoxified before disposal using a solution of:
50 g K,CrO- 25 ml ION H-SO-
145 ml H^O * *
-16- saline-P04(PBS) containing 20% normal goat serum
PBS-Tween-20 (0.05%)
Sorenson's phosphate-citrate buffer (pH = 5) containing 0.005% H,0 and
0.05% OPD. Δ
In addition, each plate had a series of
"background" control wells containing no human serum and to which one of the following had been added: — saline-P04(PBS) containing 20% normal goat serum
PBS-Tween-20 (0.05%) containing 1% normal goat serum and goat - anti-human-IgG HRP at a dilution of 1:4000
Sorenson's phosphate-citrate buffer (pH = 5) containing 0.005% H,0, and 0.05% OPD. Δ
Each test plate also had a negative and positive control serum. We tested antiserum raised against each of peptides 1-6, 31 and 64.
Analysis of the plates revealed that anti- serum raised against each of peptides 1, 2, 4 and 31 of this invention binds to the HIV virus.
4. Virus Functional Assays i. Syncytium Inhibition Assay
We assayed the peptides of this invention, as well as antisera raised to them, for their ability to inhibit syncytium formation in a variation of the assay procedure set forth in C. D. Richardson and P. W. Choppin, "Oligopeptides That Specifically Inhibit Membrane Fusion By Paramyxoviruses: Studies On The Site Of Action", Virology, 131, pp. 518-32 (1983). In our assay, we added recombinant HIV env protein, instead of live virus, to cultures of T-4 positive cells in the presence of one of the peptides of this invention, or antiserum raised thereto, and
observed the degree of inhibition of syncytium formation and cell fusion in the cultures.
We demonstrated by this assay that the peptides of this invention, as well as antisera raised to them, inhibit virus-mediated events, such as virus adsorption to cells and syncytium formation. In the assay, peptides 1-6, 31 and 64 and antiserum raised against each of peptides 1-6, 31, 64 and 78 were tested. Only peptide 3 inhibited syncytium formation.* Additionally, antiserum raised against each of peptides 1, 2, 4, 5, 31 and 78 inhibited syncytium formation.
Accordingly, this assay indicates the utility of the peptides of this invention and the antisera raised thereto as therapeutic agents. For example, administration of such peptides to an infected host may inhibit cell-to-cell transmission of the virus and virus-induced cell fusion suffi¬ ciently to prevent spread of the infection and ultimate destruction of the immune system. Alter¬ natively, these peptides may be usefully administered in a priming dose which would permit a subsequently infected host to raise neutralizing antibodies effective against the virus.
ii. Virus Neutralization Assay a. HIV Neutralization Based On Lysis Of Cells
We assayed antisera raised to the peptides of this invention, to determine their ability to neutralize HIV virus based on lysis of cells. In this assay, we mixed HIV-sensitive cells with the
* Because peptide 64 did not inhibit syncytium formation in this assay and because peptide 64 is identical to peptide 3, the inhibitory activity previously reported for peptide 3 may have been attributable to impurities present with peptide 3 in the sample assayed.
antisera, incubated them for several days and then observed the cells microscopically for lysis.
We observed that antisera to peptides 1, 2, 4, 5 and 31 of this invention neutralized HIV virus, preventing HIV infection and subsequent lysis of cells. Antiserum to each of peptides 6 and 78 did not display such activity and antisera to pep¬ tides 3 and 64 were not tested.
Such neutralizing activities indicate that the peptides of this invention and antisera thereto are useful in vaccines for preventing HIV infection. Alternatively, these peptides and antisera are useful in therapeutic compositions for inhibiting virus replication in an infected host.
C. Use Of The Peptides Of This Invention And Their Antibodies In Detecting HIV And Antibodies To HIV
Methods and diagnostic kits are presently available which are designed to detect the presence of HIV and antibodies to HIV. Peptides involved in the pathogenicity of HIV infection prepared by the processes of this invention and antibodies raised with them can also be employed in these methods and kits to detect the presence of HIV and antibodies to HIV. These peptides and their antibodies may be packaged in diagnostic kits which allow the rapid and conven¬ ient identification of AIDS carriers.
For example, the peptides of this invention or antibodies raised using them can be employed in the immunological diagnostic tests currently available for HIV antigen or antibody detection, e.g., radio- immunoassay or ELISA techniques.
In each assay, both the peptides of this invention and antibodies to these peptides, are used. The antibodies are produced by injecting laboratory animals with the peptides of this invention in a suitable solution, such as Freund's adjuvant, followed
by bleeding the animal some six weeks later, removing the red blood cells by centrifugation, and using the resulting serum. Alternatively, monoclonal antibodies to the peptides of this invention may be produced using standard hybridoma techniques.
In one type of radioimmunoassay, antibodies to an HIV peptide produced as above are attached to a solid phase, for example, the inside of a test tube. A sample of the patient's serum is added to the tube, together with a known amount of a peptide of this invention, produced as above, and labelled with a radioactive isotope such as radioactive iodine. Any HIV antigen in the patient's serum will compete with the labelled peptide for binding with the HIV antibodies. The excess liquid is removed, the test tube washed, and the amount of radioactivity measured. A positive result; i.e., that the patient's serum contains HIV antigen, is indicated by a low radio¬ activity count left in the tube, as compared with a control.
In one type of ELISA test, a microtiter plate is coated with a peptide prepared in accordance with this invention, and to this is added a sample of patient's serum. After a period of incubation permitting interaction of any HIV antibody present in the serum with the HIV antigen, the plate is washed. A preparation of anti-human antibodies, raised in a laboratory animal by injection of semi- purified human immunoglobulin, and then linked to an enzyme, is added. Incubation allows an antibody- antigen reaction to take place, and the plate is then rewashed. Thereafter, enzyme substrate is added to the microtiter plate and incubated for a period of time to allow the enzyme to react with the sub- strate. The absorbance of the final preparation is then measured. A large change in absorbance indicates
a positive result, i.e., that the patient's serum contains antibodies to HIV.
While we have hereinbefore presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other enbodiments which utilize the process of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which have been presented hereinbefore by way of example.
Claims
1. A peptide involved in the pathogenesis of the HIV virus selected from the group consisting of peptides characterized by an amino acid sequence derived substantially from the region between about amino acid 600 and amino acid 750 of the HIV env gene.
2. A peptide according to claim 1, selected from the group consisting of peptides characterized by a sequence of amino acids consist¬ ing substantially of amino acid sequences of the formulae:
PWNASWSNKSLEQIWNN, LLELDKWASLWNWF, E IWNNMTWMEWD, LPIPRGPDRPEGIEEEGGERDRDR and D-retro forms thereof.
3. A peptide involved in the pathogenesis of the HIV virus characterized by a sequence of amino acids selected from the group consisting of peptides consisting substantially of amino acid sequences of the formulae: RIKQIINMWQEVGKAMYAPPISGQI, VKIEPLGVAPTKAKRRWQREKRA, NSSSGRMIMEKGEIKNCS, SVEINCTRPNNNTRKSI and D-retro forms thereof.
4. A pharmaceutically acceptable composi¬ tion for treating patients to protect them for some time against HIV infection which comprises an immuno- logically effective amount of at least one peptide according any one of claims 1 to 3.
5. A method for treating patients to protect them for some time against HIV infection comprising the step of treating said patients in a pharmaceutically acceptable manner with the composi¬ tion according to claim 4.
6. A pharmaceutically acceptable composi¬ tion for treating HIV infection in patients which comprises at least one peptide according to any one of claims 1 to 3 in an amount effective to lessen the severity of the HIV infection.
7. A method for treating HIV infection in patients comprising the step of treating said patients in a pharmaceutically acceptable manner with the composition according to claim 6.
8. A method for detecting .antibodies to
HIV antigen in samples of blood, tissue or semen characterized by at least one peptide according to any one of claims 1 to 3.
9. A method for detecting HIV antigens in samples of blood, tissue or semen characterized by an antibody to at least one peptide according to any one of claims 1 to 3.
10. An HIV diagnostic kit characterized by at least one peptide according to any one of claims 1 to 3 or at least one antibody raised against one or more of those peptides.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87362186A | 1986-06-12 | 1986-06-12 | |
US873,621 | 1986-06-12 | ||
US4193687A | 1987-04-24 | 1987-04-24 | |
US041,936 | 1987-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1987007616A1 true WO1987007616A1 (en) | 1987-12-17 |
Family
ID=26718709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1987/001294 WO1987007616A1 (en) | 1986-06-12 | 1987-06-09 | Peptides involved in the pathogenesis of hiv infection |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0269712A4 (en) |
JP (1) | JPH01501547A (en) |
AU (1) | AU617088B2 (en) |
NZ (1) | NZ220653A (en) |
WO (1) | WO1987007616A1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0284587A2 (en) * | 1987-03-27 | 1988-09-28 | Syntello Ab | Synthetic peptide antigens for the detection of HIV-1 infection |
WO1988009339A1 (en) * | 1987-05-29 | 1988-12-01 | Labsystems Oy | Hiv polypeptide, its preparation and use in detection of hiv antibodies |
EP0328403A2 (en) * | 1988-02-12 | 1989-08-16 | United Biomedical Inc. | Synthetic peptides related to the HIV-GP120-env-protein, and their use |
EP0339504A2 (en) * | 1988-04-26 | 1989-11-02 | The Du Pont Merck Pharmaceutical Company | Human immunodeficiency virus (HIV) env-coded peptide capable of eliciting HIV-inhibiting antibodies in mammals |
WO1990003984A1 (en) * | 1988-10-03 | 1990-04-19 | Repligen Corporation | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids |
EP0400076A1 (en) * | 1988-01-26 | 1990-12-05 | Us Health | A synthetic antigen evoking anti-hiv response. |
WO1990014842A1 (en) * | 1989-05-31 | 1990-12-13 | Medical Research Council | Vaccine against hiv |
EP0470184A1 (en) * | 1989-04-25 | 1992-02-12 | Tanox Biosystems Inc | Antibodies specific for cd4-binding domain of hiv. |
WO1992005800A1 (en) * | 1990-09-27 | 1992-04-16 | Syntello Vaccin Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
US5126399A (en) * | 1986-04-30 | 1992-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation and use of site-directed immunologic reagents |
US5166050A (en) * | 1986-08-20 | 1992-11-24 | Bristol-Myers Squibb Company | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections |
WO1992021377A1 (en) * | 1991-06-03 | 1992-12-10 | Syntello Inc. | Peptides for use in induction of t cell activation against hiv-1 |
EP0525828A2 (en) * | 1986-08-01 | 1993-02-03 | Repligen Corporation | Recombinant polypeptides and their uses, including assay for aids virus |
EP0565164A1 (en) * | 1992-03-26 | 1993-10-13 | The New York Blood Center | Synthetic polypeptides as inhibitors of HIV-1 |
US5346989A (en) * | 1990-08-22 | 1994-09-13 | Syntello Vaccine Development Kb | Peptides for use in induction of T cell activation against HIV-1 |
EP0667786A1 (en) * | 1992-08-27 | 1995-08-23 | Deakin Research Limited | Retro-, inverso-, and retro-inverso synthetic peptide analogues |
US5562905A (en) * | 1988-04-26 | 1996-10-08 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
US5693752A (en) * | 1992-05-14 | 1997-12-02 | Hermann Katinger | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
AU692777B2 (en) * | 1993-06-07 | 1998-06-18 | Duke University | Synthetic peptide inhibitors of HIV transmission |
EP0868196A1 (en) * | 1995-10-20 | 1998-10-07 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
US5820865A (en) * | 1988-01-26 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides |
US5840313A (en) * | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
US5976541A (en) * | 1988-01-26 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope |
US6309880B1 (en) * | 1989-04-25 | 2001-10-30 | Tanox, Inc. | Antibodies specific for CD4-binding domain of HIV-1 |
US6455244B1 (en) * | 1994-03-14 | 2002-09-24 | Biomerieux S.A. | Methods for the detection of antibodies associated with autoimmune disorders and infectious agents employing immunoretroid peptides derived from antigens associated with said disorders and agents |
US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
EP1714153A2 (en) * | 2004-02-06 | 2006-10-25 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
WO2007039458A2 (en) * | 2005-09-21 | 2007-04-12 | Cytos Biotechnology Ag | Hiv peptide conjugates and uses thereof |
WO2007098257A2 (en) * | 2006-02-27 | 2007-08-30 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Hiv tev compositions and methods of use |
US7803524B2 (en) | 1994-02-23 | 2010-09-28 | Siemens Healthcare Diagnostics Products Gmbh | Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS |
EP1466924B1 (en) * | 2003-04-11 | 2011-05-04 | Institut Pasteur | Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
ATE299029T1 (en) * | 1998-03-23 | 2005-07-15 | Trimeris Inc | METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS (T-20) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE373010T1 (en) * | 1984-10-18 | 2007-09-15 | Pasteur Institut | GAG ANTIGEN AND ITS USE FOR DETECTING LAV INFECTION, AND IN IMMUNOGENIC COMPOSITIONS |
GB8525615D0 (en) * | 1985-10-17 | 1985-11-20 | Hoffmann La Roche | Polypeptides |
US4772547A (en) * | 1986-02-03 | 1988-09-20 | Hoffmann-La Roche Inc. | HTLV-III envelope peptides |
-
1987
- 1987-06-09 JP JP62503612A patent/JPH01501547A/en active Pending
- 1987-06-09 WO PCT/US1987/001294 patent/WO1987007616A1/en not_active Application Discontinuation
- 1987-06-09 AU AU75404/87A patent/AU617088B2/en not_active Ceased
- 1987-06-09 EP EP19870903968 patent/EP0269712A4/en not_active Withdrawn
- 1987-06-11 NZ NZ220653A patent/NZ220653A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
Non-Patent Citations (3)
Title |
---|
Cell, Volume 45, issued 06 June 1986, (STARCICH et al), "Identification and Characterization of Conserved and Variable Regions in the envelope Gene of HTLV-III/LAV, the Retrovirus of Aids, pages 637-648. * |
Science, (Washington, D.C., USA), Volume 231 issued March 1986, (KENNEDY et al), "Anti-serum to a Synthetic Peptide Recognizes the HTLV-III Envelope Glycoprotein", pages 1556-1559. see page 1556 in particular. * |
See also references of EP0269712A4 * |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126399A (en) * | 1986-04-30 | 1992-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation and use of site-directed immunologic reagents |
EP0525828A2 (en) * | 1986-08-01 | 1993-02-03 | Repligen Corporation | Recombinant polypeptides and their uses, including assay for aids virus |
EP0525828A3 (en) * | 1986-08-01 | 1993-02-24 | Repligen Corporation | Recombinant polypeptides and their uses, including assay for aids virus |
US5166050A (en) * | 1986-08-20 | 1992-11-24 | Bristol-Myers Squibb Company | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections |
EP0284587A3 (en) * | 1987-03-27 | 1990-11-22 | Syntello Ab | Synthetic peptide antigens for the detection of hiv-1 infection |
EP0284587A2 (en) * | 1987-03-27 | 1988-09-28 | Syntello Ab | Synthetic peptide antigens for the detection of HIV-1 infection |
WO1988009339A1 (en) * | 1987-05-29 | 1988-12-01 | Labsystems Oy | Hiv polypeptide, its preparation and use in detection of hiv antibodies |
EP0400076A4 (en) * | 1988-01-26 | 1991-11-13 | Us Health | A synthetic antigen evoking anti-hiv response |
US5820865A (en) * | 1988-01-26 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides |
EP0400076A1 (en) * | 1988-01-26 | 1990-12-05 | Us Health | A synthetic antigen evoking anti-hiv response. |
US5976541A (en) * | 1988-01-26 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
EP0328403A3 (en) * | 1988-02-12 | 1991-09-25 | United Biomedical Inc. | Synthetic peptides related to the hiv-gp120-env-protein, and their use |
EP0328403A2 (en) * | 1988-02-12 | 1989-08-16 | United Biomedical Inc. | Synthetic peptides related to the HIV-GP120-env-protein, and their use |
EP0339504A3 (en) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
JPH02160800A (en) * | 1988-04-26 | 1990-06-20 | E I Du Pont De Nemours & Co | Human immunodeficiency virus (hiv) |
EP0339504A2 (en) * | 1988-04-26 | 1989-11-02 | The Du Pont Merck Pharmaceutical Company | Human immunodeficiency virus (HIV) env-coded peptide capable of eliciting HIV-inhibiting antibodies in mammals |
US5562905A (en) * | 1988-04-26 | 1996-10-08 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
AU632475B2 (en) * | 1988-04-26 | 1993-01-07 | Du Pont Merck Pharmaceutical Company, The | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
WO1990003984A1 (en) * | 1988-10-03 | 1990-04-19 | Repligen Corporation | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids |
EP0470184A1 (en) * | 1989-04-25 | 1992-02-12 | Tanox Biosystems Inc | Antibodies specific for cd4-binding domain of hiv. |
EP0470184A4 (en) * | 1989-04-25 | 1992-10-07 | Tanox Biosystems, Inc. | Antibodies specific for cd4-binding domain of hiv |
US6309880B1 (en) * | 1989-04-25 | 2001-10-30 | Tanox, Inc. | Antibodies specific for CD4-binding domain of HIV-1 |
WO1990014842A1 (en) * | 1989-05-31 | 1990-12-13 | Medical Research Council | Vaccine against hiv |
US5346989A (en) * | 1990-08-22 | 1994-09-13 | Syntello Vaccine Development Kb | Peptides for use in induction of T cell activation against HIV-1 |
US5589175A (en) * | 1990-09-27 | 1996-12-31 | Syntello Vaccine Development Kb | Peptides for induction of neutralizing antibodies against human immunodeficiency virus |
WO1992005800A1 (en) * | 1990-09-27 | 1992-04-16 | Syntello Vaccin Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
US5840313A (en) * | 1990-09-27 | 1998-11-24 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
WO1992021377A1 (en) * | 1991-06-03 | 1992-12-10 | Syntello Inc. | Peptides for use in induction of t cell activation against hiv-1 |
AU662534B2 (en) * | 1991-06-03 | 1995-09-07 | Syntello Vaccine Development Ab | Peptides for use in induction of T cell activation against HIV-1 |
EP0565164A1 (en) * | 1992-03-26 | 1993-10-13 | The New York Blood Center | Synthetic polypeptides as inhibitors of HIV-1 |
US5444044A (en) * | 1992-03-26 | 1995-08-22 | New York Blood Center | Synthetic polypeptides as inhibitors of HIV-1 |
US5693752A (en) * | 1992-05-14 | 1997-12-02 | Hermann Katinger | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates |
US5756674A (en) * | 1992-05-14 | 1998-05-26 | Herman Katinger | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates |
EP0667786A4 (en) * | 1992-08-27 | 1997-08-06 | Deakin Res Ltd | Retro-, inverso-, and retro-inverso synthetic peptide analogues. |
US6261569B1 (en) | 1992-08-27 | 2001-07-17 | Deakin Research Limited | Retro-, inverso- and retro-inverso synthetic peptide analogues |
EP0667786A1 (en) * | 1992-08-27 | 1995-08-23 | Deakin Research Limited | Retro-, inverso-, and retro-inverso synthetic peptide analogues |
AU692777B2 (en) * | 1993-06-07 | 1998-06-18 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US7803524B2 (en) | 1994-02-23 | 2010-09-28 | Siemens Healthcare Diagnostics Products Gmbh | Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS |
US6455244B1 (en) * | 1994-03-14 | 2002-09-24 | Biomerieux S.A. | Methods for the detection of antibodies associated with autoimmune disorders and infectious agents employing immunoretroid peptides derived from antigens associated with said disorders and agents |
EP0868196A4 (en) * | 1995-10-20 | 2004-11-24 | Univ Duke | Synthetic vaccine for protection against human immunodeficiency virus infection |
EP0868196A1 (en) * | 1995-10-20 | 1998-10-07 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
EP1466924B1 (en) * | 2003-04-11 | 2011-05-04 | Institut Pasteur | Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV |
EP1714153A2 (en) * | 2004-02-06 | 2006-10-25 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
WO2007039458A2 (en) * | 2005-09-21 | 2007-04-12 | Cytos Biotechnology Ag | Hiv peptide conjugates and uses thereof |
WO2007039458A3 (en) * | 2005-09-21 | 2007-06-07 | Cytos Biotechnology Ag | Hiv peptide conjugates and uses thereof |
WO2007098257A2 (en) * | 2006-02-27 | 2007-08-30 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Hiv tev compositions and methods of use |
WO2007098257A3 (en) * | 2006-02-27 | 2007-12-06 | Us Gov Health & Human Serv | Hiv tev compositions and methods of use |
Also Published As
Publication number | Publication date |
---|---|
AU7540487A (en) | 1988-01-11 |
JPH01501547A (en) | 1989-06-01 |
EP0269712A4 (en) | 1990-06-26 |
AU617088B2 (en) | 1991-11-21 |
EP0269712A1 (en) | 1988-06-08 |
NZ220653A (en) | 1990-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1987007616A1 (en) | Peptides involved in the pathogenesis of hiv infection | |
US8110203B2 (en) | Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes | |
EP0330359A2 (en) | Composition useful in the diagnosis and treating of HIV-1 infection | |
JPH02160800A (en) | Human immunodeficiency virus (hiv) | |
EP0311219B1 (en) | Oligopeptides and their use for diagnostic and vaccination purposes for AIDS and ARC | |
US5777074A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1) | |
EP0311675A1 (en) | Immunotherapeutic methods and compositions | |
GB2196634A (en) | Monoclonal antibodies to HIV and related peptides | |
DEVASH et al. | C-terminal fragments of gpl20 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals | |
US6008044A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC) | |
US5017688A (en) | Peptides involved in the pathogenesis of HIV infection | |
RU2337922C2 (en) | ISOLATED POLYPEPTIDES BASED ON NEUTRALISING OF PROTEIN p17 OF HIV VIRUS, USED AS VACCINES, AND NEUTRALISING ANTI-p17-ANTIBODIES, SPECIFICALLY RECOGNISING SAID NEUTRALISING | |
Boudet et al. | Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120 | |
US4943627A (en) | Peptides involved in the pathogenesis of HIV infection | |
WO1989005821A1 (en) | Hiv-related antigens and antibodies | |
AU2006200454B2 (en) | Compositions and methods for treating viral infections | |
KR920001772B1 (en) | Human immunodeficiency virus(hiv)enn-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals | |
WO1989005820A1 (en) | Hiv-related antigens and antibodies | |
JP2002503205A (en) | Goat arthritis-encephalitis virus provides immune protection against HIV-1 infection | |
AU623097B2 (en) | Oligopeptides and their use for diagnostic and vaccination purposes for aids and arc | |
Jones-Trower et al. | Characterization and Enhanced Processing of Soluble, Oligomeric gp140 Envelope Glycoproteins Derived from Human Immunodeficiency Virus Type-1 Primary Isolates | |
AU6655300A (en) | Compositions and methods for treating infections | |
AU2004208648A1 (en) | Compositions and methods for treating infections | |
AU2006200455A1 (en) | Compositions and methods for treating viral infections | |
WO1992022579A1 (en) | MIMIC PEPTIDES OF gp120 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1987903968 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1987903968 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1987903968 Country of ref document: EP |